GeneralConnection.com ➔ Dictionary
Dictionary Search

indolent

Synonyms

Adjective

1. faineant

2. lazy, otiose, slothful, work-shy, idle, inactive

Usage
Long-Term PIONEER Data Reinforce Avapritinib's Role in Indolent Systemic Mastocytosis - Dermatology Times
Future Directions in Indolent Systemic Mastocytosis Treatment - MedPage Today
1 Reframing “Benign” Disease: The Modern Clinical Impact of Indolent Systemic Mastocytosis - HCPLive
Indolent primary cutaneous B-cell lymphomas resemble persistent antigen reactions without signs of dedifferentiation - Nature
HARBOR Trial Aims to Further Elucidate Potential Role for Elenestinib in Indolent Systemic Mastocytosis - OncLive
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches - Targeted Oncology
Phase 2 Trial Will Evaluate CD19 t-haNK Combo in Indolent Lymphomas - CancerNetwork
Indolent Lymphoma Treatment Market Analysis By Application, - openPR.com
Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis - Cureus
Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas - The New England Journal of Medicine
ASH 2025 | Congress coverage: Indolent and mantle cell NHL - Lymphoma Hub
Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis - PR Newswire
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - Business Wire
Dr Radia on the Continued Investigation of Elenestinib in Indolent Systemic Mastocytosis - OncLive
KIT D816V Biology and Longitudinal Symptom Assessment in Indolent Systemic Mastocytosis - HCPLive
Avapritinib's Effect Durable in Indolent Systemic Mastocytosis - MedPage Today
Long-Term Avapritinib Use Improves Bone Health Regardless of Concomitant Anti-Osteoporosis Therapy in Indolent SM - OncLive
Dr Tashi on Updated Efficacy Data for Avapritinib in Indolent Systemic Mastocytosis - OncLive
Avapritinib Yields Sustained Symptom Reduction and Safety in Indolent SM - OncLive
Dr Tashi on the Effect of Avapritinib on Long-Term Bone Health in Indolent Systemic Mastocytosis - OncLive
Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma – a case report - Frontiers
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5 - The ASCO Post
Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting - PR Newswire
Law Does Not Favour The Indolent: Supreme Court Sets Aside Arbitration Initiated After 21-Year Delay - Live Law
"Lethargic, Tardy and Indolent," Supreme Court Pulls Up Odisha Govt For 4 Months Delay in Filing SLP - LawBeat
Soludo pays unscheduled visit to Anambra secretariat, warns indolent workers - Business News Nigeria
Lethargic, Tardy & Indolent: SC Rebukes Odisha Govt For Delay In Filing SLP - OdishaBytes
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas - NTB Kommunikasjon
What Chemo-Free Immunotherapy Combos Have Potential in Indolent Lymphomas? - CancerNetwork
How Will Indolent Lymphoma/B-Cell NHL Care Be Improved in the Future? - CancerNetwork
How Promising Are Immunotherapy Combos in Indolent Lymphoma? - CancerNetwork
Court officials suspended for drug trafficking, forgery, stealing; indolent Sharia judge gets warning - Peoples Gazette Nigeria
Avapritinib Benefit Persists at 3 Years for Indolent Systemic Mastocytosis - Oncology News Central
Elenestinib May Be Safer Than Traditional KIT Inhibitors in Indolent Systemic Mastocytosis - OncLive
What AEs Should Physicians Be Aware of With Bispecifics in Indolent Lymphoma? - CancerNetwork
Indolent Tumour of the Upper Lip: A Case of Lobulated Acinic Cell Carcinoma - Cureus
Ominous-appearing serosal findings on PSMA imaging might belie indolent clinical course - Nature
Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight - PR Newswire
Current Standards of Care to Treat Patients With Indolent Systemic Mastocytosis - HCPLive
Looking Ahead in Indolent Systemic Mastocytosis Treatment: Data Gaps and Hope for a Cure - HCPLive
Lame Excuses, State Is Utterly Lethargic, Tardy and Indolent: Supreme Court Slams Odisha Govt for Delayed Appeal - LawChakra
‘Indolent and not photogenic’: can I make my reluctant cat a social media star in seven days? - The Guardian
The Clinical Significance of a Durable Treatment for Indolent Systemic Mastocytosis - HCPLive
Considerations for Renaming Indolent Prostate Cancer in Different Practice Settings - Matthew Cooperberg & Nicolás Villareal Trujillo - UroToday
Avapritinib versus Placebo in Indolent Systemic Mastocytosis - NEJM Evidence
The Heterogeneous Clinical Presentations of Indolent Systemic Mastocytosis - HCPLive
Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis - OncLive
‘Utterly Lethargic, Tardy And Indolent’: Supreme Court Dismisses Orissa Govt’s SLP As Time Barred - Verdictum
18th International Conference on Malignant Lymphoma (ICML) congress coverage | Indolent and mantle cell NHL - Lymphoma Hub
San Diego workshops to focus on indolent systemic mastocytosis - Times of San Diego
Many Patients with ISM Have Lower Survival - Cleveland Clinic
Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract - Haematologica
EHA 2025 | Indolent and mantle cell NHL - Lymphoma Hub
Monjuvi scores a qualified indolent lymphoma success | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis - Haematologica
Indolent nodal T follicular helper cell lymphomas—A case series - Blood Cancer Journal - Nature
FDA Approves Avapritinib for Indolent Systemic Mastocytosis - OncLive
When Teratomas Turn Brutal: From Indolent to Invasive in Stage IIIB Ovarian Squamous Cell Carcinoma - Cureus
Understanding Indolent Systemic Mastocytosis (ISM): Symptoms and Impact - HCPLive
FDA Approves Avapritinib in Indolent Systemic Mastocytosis - CancerNetwork
A new treatment without chemotherapy for indolent clinical forms of mantle cell lymphoma - Hospital Clínic Barcelona
Bureaucratic Delay no Ground for Condonation; Supreme Court dismisses SLP as time-barred for State being ‘utterly lethargic, tardy and indolent’ - SCC Online
Dr. Goy on the Clinical Implications of Treating Indolent MCL - OncLive
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy - The New England Journal of Medicine
The Remaining Role for Radioimmunotherapy in Indolent Lymphoma - ASCO Daily News
Defining Indolent Relapse Multiple Myeloma - Pharmacy Times
Autoimmunity promotes chronic lymphocytic leukemia progression in an indolent disease model - Nature
Bispecific antibodies in indolent B-cell lymphomas - Frontiers
More Treatments for Indolent Lymphoma in Clinic Soon? “Exciting Updates” From ASH 2024 - Oncology News Central
FDA Approves Avapritinib for Indolent Systemic Mastocytosis - The ASCO Post
Function and Circulation of the Retina and Choroid in Case of Indolent Nonprogressive Multifocal Choroidal Lesions - Cureus
Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma - The ASCO Post
Beyond Serum Tryptase: Exploring Additional Testing Approaches for Indolent Systemic Mastocytosis - OncLive
Axi-Cel Efficacy in R/R Indolent Non-Hodgkin Lymphoma Sustained at 5 Years - Targeted Oncology
FDA Approves Avapritinib for Indolent Systemic Mastocytosis - Targeted Oncology
Transforming Management of Indolent Systemic Mastocytosis With Precision Medicine - EMJ
Exploring Novel Combinations in Indolent Lymphomas - Targeted Oncology
Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight - Moomoo
Multidisciplinary Collaboration Is Vital for Timely, Definitive Diagnosis of Indolent Systemic Mastocytosis - OncLive
Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial - The Lancet
Direct-Acting Antivirals in HCV-Associated Indolent Non-Hodgkin Lymphomas - The ASCO Post
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma - Cure Today
Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis - OncLive
Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis - OncLive
Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor - Journal of Nuclear Medicine
Enterome presents positive Phase 2 interim results in - GlobeNewswire
The Indolent Nature of Chronic Lymphocytic Leukemia - Cure Today
Nearly One-Fifth of Screened Lung Cancer Cases May Be Indolent - CancerNetwork
Advances in Lymphoma Research - National Cancer Institute (.gov)
T‐PLL Presenting with an Indolent Course - Thammahong - 2024 - Case Reports in Hematology - Wiley Online Library
Identification of superficial invasive and indolent lymphomatous lymph nodes by multiple ultrasonographic vascular imaging - Nature
Study Supports Bendamustine-Rituximab as Standard-of-Care in Patients With Indolent Non-Hodgkin Lymphoma - Pharmacy Times
Shift to targeted therapies continues in relapsed/refractory indolent non-Hodgkin lymphoma - Healio
Avapritinib Receives Support for Indolent Systemic Mastocytosis Indication in Europe - Docwire News
Behind the Indolent Facade: Uncovering the Molecular Features and Malignancy Potential in Lung Minimally Invasive Adenocarcinoma by Single-Cell Transcriptomics - Wiley
Indolent Lymphoma: A More Complex Malignancy Than Once Thought - The ASCO Post
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis - PR Newswire
Indolent pocket wound in a cat - Vet Times
Clinical and Molecular Features May Predict Indolent Chronic Myelomonocytic Leukemia - Cancer Therapy Advisor
An 84-Year-Old Woman With an Indolent B-Cell Lymphoma - CancerNetwork
Foreign Language Equivalents
Foreign Language Equivalents of 'indolent'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
,   indolenr,   indolennt,   indoletn,   indolemt,   indollent,   indokent,   iindolent,   indlent,   idolent,   indoolent,   indoent,   indolet,   indolnet,   inodlent,   idnolent,   inddolent,   inolent,   indilent,   indloent,   indoleny,   undolent,   indplent,   ondolent,   imdolent,   indoelnt,   indolen,   indoleent,   ibdolent,   indolnt,   indolwnt,   ndolent,   indolebt,   indolentt,   nidolent,   indolrnt,   inndolent,   indo;ent,   infolent,   insolent
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z